SynthesisFrontiers in oncology2026
Risk prediction models for venous thromboembolism in lung cancer patients after surgery: a systematic review and meta-analysis.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Risk prediction models for venous thromboembolism (VTE) in lung cancer patients undergoing surgery have increased substantially in recent years. However, the methodological quality, predictive performance, and clinical applicability of these models have yet to be systematically assessed. Objective: This study aimed to systematically evaluate the published literature on the development and validation of postoperative VTE risk prediction models for patients with lung cancer. Design: A systematic review and meta-analysis of observational studies was conducted. Methods: A comprehensive search of CNKI, Wanfang, VIP, PubMed, Web of Science, The Cochrane Library, CINAHL, and Embase was conducted from inception to November 22, 2025. The data extracted from the included studies encompassed a range of characteristics, including design elements, predictors, model development strategies, validation approaches, and performance metrics. The Prediction Model Risk of Bias Assessment Tool (PROBAST) was utilized to evaluate the risk of bias and applicability. A meta-analysis of area under the receiver operating characteristic curve (AUC) values from validated models was performed using random-effects methods. Results: A total of 4,700 records were identified, and after screening, twenty studies involving twenty prediction models were included. The majority of the studies were retrospective and single-center, and all were adjudged to have a high risk of bias according to PROBAST. Logistic regression emerged as the predominant modeling approach, while a limited number of studies adopted machine learning methods, including XGBoost and stacked models. The most frequently utilized predictors were D-dimer and age. The extent of reported model discrimination exhibited significant variability, with AUC values ranging from 0.66 to 0.99. A total of eight models that had undergone validation were deemed eligible for the quantitative synthesis, resulting in a pooled AUC of 0.85 (95% confidence interval [CI]: 0.78-0.93). However, substantial heterogeneity was observed ( Conclusion: While several models showed some discriminatory ability, all included studies demonstrated a high risk of bias and limitations in applicability. The extant evidence does not support the routine clinical use of existing postoperative VTE prediction models in lung cancer patients. Future studies should adopt rigorous methodological frameworks, ensure adequate sample sizes, apply standardized predictor handling, and conduct multicenter external validation to improve the reliability and clinical utility of prediction models. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251232098.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.